1. Home
  2. |Insights
  3. |NASA Pushes FAR, Far Away for Commercial Crew Program

NASA Pushes FAR, Far Away for Commercial Crew Program

Client Alert | less than 1 min read | 12.29.11

In a recent report, GAO questioned whether NASA could ensure adequate price competition using a FAR-based acquisition approach for its Commercial Crew Program because, according to the GAO, substantially reduced funding would jeopardize NASA’s plan to award multiple contracts for the program’s integrated design phase.  NASA concurred, and on December 15, 2011, announced that it would abandon using FAR-based contracting for the next stage of the program and instead would rely on “multiple, competitively awarded Space Act Agreements” to foster competition and give NASA “the flexibility to adjust technical direction, milestones and funding” in order to decrease reliance on foreign governments for sending Americans into space.

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...

View All Insights